Stemrim Inc. (4599) Press Release
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
Earlier from Stemrim
- StemRIM Announces Patent Registration for SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in South Korea
- StemRIM Announces Patent Registration (Mexico) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
- StemRIM Announces Patent Registration (Canada) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy, Old Myocardial Infarction
- StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (SR-GT1) Aimed at Curative Treatment of DEB in,South Korea